Molnupiravir’s authorisation should be re-evaluated after the Panoramic trial is reported
Brophy’s editorial on Merck’s Move-Out trial of molnupiravir raises important concerns about the approval of molnupiravir to treat outpatients with covid-19 in the United Kingdom.1 Molnupiravir has…
